• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    IGC Pharma, Inc. Common Stock (NY:IGC)

    0.3018 +0.0053 (+1.79%)
    Streaming Delayed Price Updated: 11:34 AM EDT, May 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about IGC Pharma, Inc. Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    17 18 Next >
    News headline image
    New to The Street Broadcasts Show #752 on Bloomberg Television Featuring Graphene Manufacturing Group (OTCQX:GMGRF), T-REX Acquisition Corp (NASDAQ:TRXA), KITON, and Roadzen (NASDAQ:RDZN)
    Via ACCESS Newswire
    News headline image
    GLOBAL MARKETS SPOTLIGHT: New to The Street Show #748 Delivers High-Impact CEO Interviews and Spotlight TV Commercials Across Bloomberg to 250M+ Households Worldwide
    Via ACCESS Newswire
    News headline image
    IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase
    Via ACCESS Newswire
    News headline image
    New to The Street to Air Show #747 Tonight on Fox Business Network Featuring Performance Golf, CitroTech, Lee Gause, CISO Global, and Lost Soldier Oil and Gas
    Via ACCESS Newswire
    News headline image
    New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global
    Via ACCESS Newswire
    News headline image
    IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion
    Via ACCESS Newswire
    News headline image
    IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia
    Via ACCESS Newswire
    News headline image
    New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Vivos Therapeutics
    Via ACCESS Newswire
    News headline image
    IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout
    Via ACCESS Newswire
    News headline image
    IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease
    Via ACCESS Newswire
    News headline image
    IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness
    Via ACCESS Newswire
    News headline image
    New to The Street Broadcasts Show #740 on Bloomberg Television at 6:30 PM EST Featuring Medicus (MDCX), Acme Markets- Canton Foundation, Alpha Ton Capital (ATON), and Virtuix Holdings (NASDAQ:VTIX)
    Via ACCESS Newswire
    News headline image
    New to The Street and IGC Pharma (NYSE American:IGC) Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market Positioning
    Via ACCESS Newswire
    News headline image
    IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025
    Via ACCESS Newswire
    News headline image
    IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026
    Via ACCESS Newswire
    News headline image
    IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research
    Via ACCESS Newswire
    News headline image
    IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets
    Via ACCESS Newswire
    News headline image
    IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
    Via ACCESS Newswire
    News headline image
    IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances
    Via ACCESS Newswire
    News headline image
    IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets
    Via ACCESS Newswire
    News headline image
    IGC Pharma Announces Equity Research Update by Alliance Global Partners
    Via ACCESS Newswire
    News headline image
    IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center
    Via ACCESS Newswire
    News headline image
    IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation
    Via ACCESS Newswire
    News headline image
    IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York
    Via ACCESS Newswire
    News headline image
    IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia
    Via ACCESS Newswire
    News headline image
    IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability
    Via ACCESS Newswire
    News headline image
    IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial
    Via ACCESS Newswire
    News headline image
    IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum
    Via ACCESS Newswire
    News headline image
    IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines
    Via ACCESS Newswire
    News headline image
    IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75."
    Via ACCESS Newswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    17 18 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.